Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 1 Jun 2024 |
| Transactions in Connection with Share Buy-back Program | 27 May 2024 |
| Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting | 23 May 2024 |
| Transactions in Connection with Share Buy-back Program | 21 May 2024 |
| Genmab Completes Acquisition of ProfoundBio | 21 May 2024 |
| Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress | 14 May 2024 |